Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET
Company Participants
Todd Tushla - Vice President, Investor Relations
Kevin Gorman - Chief Executive Officer
Matt Abernethy - Chief Financial Officer
Eiry Roberts - Chief Medical Officer
Eric Benevich - Chief Commercial Officer
Kyle Gano - Chief Business Development and Strategy Officer
Conference Call Participants
Phil Nadeau - TD Cowen
Chris Shibutani - Goldman Sachs
Paul Matteis - Stifel
Tazeen Ahmad - Bank of America
Brian Abrahams - BRC Capital Markets
Josh Schimmer - Cantor
Leon Wang - Barclays
Anupam Rama - JPMorgan
Jay Olson - Oppenheimer
Marc Goodman - Leerink Partners
Michael Riad - Morgan Stanley
Myles Minter - William Blair
Yatin Suneja - Guggenheim Partners
Laura Chico - Wedbush Securities
Sumant Kulkarni - Canaccord
David Amsellem - Piper Sandler
Ash Verma - UBS
Ami Fadia - Needham
Uy Ear - Mizuho
Conor MacKay - BMO Capital Markets
Operator
Good day, everyone. And welcome to the Neurocrine Biosciences Reports third quarter results. At this time, all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions]
Please note this call is being recorded and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Todd Tushla, Vice President of Investor Relations. Please go ahead.
Todd Tushla
Good morning. Happy Halloween and thanks for joining Neurocrine’s third quarter 2023 earnings call. I’m pleased to be joined by Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eiry Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer.
During today’s call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After prepared remarks, we’re going to try and get to all of your questions. So, Kevin, take it away.
Kevin Gorman
Thank you, Todd, and good morning, everyone. It’s been a very, very good quarter. I’m not going to go into really any detail. I think everyone else who’s going to be talking on the call will, and as always, we just want to spend as much time with your questions as possible.